Members |
targetComponentId |
Adverse reaction to agent affecting blood constituents NOS |
Adverse reaction to drug |
Adverse reaction to agent affecting blood constituents NOS |
Adverse reaction to drug |
Adverse reaction to agents primarily affecting blood constituents |
Adverse reaction to drug |
Adverse reaction to agents primarily affecting blood constituents |
Adverse reaction to drug |
Adverse reaction to antiasthmatic NOS |
Adverse reaction to drug |
Adverse reaction to anticonvulsant and antiparkinsonism drugs NOS |
Adverse reaction to drug |
Adverse reaction to anticonvulsants and anti-parkinsonism drugs |
Adverse reaction to drug |
Adverse reaction to antiparkinsonism drug |
Adverse reaction to drug |
Adverse reaction to antiparkinsonism drugs NOS |
Adverse reaction to drug |
Adverse reaction to bromine compound |
Adverse reaction caused by bromine and/or bromine compound (disorder) |
Adverse reaction to cardiac glycoside |
Adverse reaction to Digitalis glycoside |
Adverse reaction to cardiac glycosides NOS |
Adverse reaction to Digitalis glycoside |
Adverse reaction to central nervous system depressant |
Adverse reaction to drug |
Adverse reaction to central nervous system muscle-tone depressants NOS |
Adverse reaction to drug |
Adverse reaction to clomocycline sodium |
Adverse reaction to clomocycline |
Adverse reaction to clorazepate dipotassium |
Adverse reaction to clorazepate |
biverkning av vaccin mot SARS-CoV-2 |
Adverse reaction to COVID-19 vaccine |
Adverse reaction to dental drugs topically applied |
Adverse reaction to drug |
Adverse reaction to drug primarily affecting the autonomic nervous system NOS |
Adverse reaction to drug |
Adverse reaction to drug primarily affecting the cardiovascular system NOS |
Adverse reaction to drug |
Adverse reaction to drug primarily affecting the cardiovascular system NOS |
Adverse reaction to drug |
Adverse reaction to drugs primarily affecting autonomic nervous system |
Adverse reaction to drug |
Adverse reaction to drugs primarily affecting gastrointestinal system |
Adverse reaction to drug |
Adverse reaction to drugs primarily affecting gastrointestinal system |
Adverse reaction to drug |
Adverse reaction to drugs primarily affecting skin and mucous membrane, ophthalmological, otorhinolaryngological and dental drugs |
Adverse reaction to drug |
Adverse reaction to drugs primarily affecting the cardiovascular system |
Adverse reaction to drug |
Adverse reaction to drugs primarily affecting the cardiovascular system |
Adverse reaction to drug |
Adverse reaction to drugs primarily affecting the gastrointestinal system NOS |
Adverse reaction to drug |
Adverse reaction to liver preparations and other antianemic agents NOS |
Adverse reaction to drug |
Adverse reaction to other agent affecting blood constituents |
Adverse reaction to drug |
Adverse reaction to other agent affecting blood constituents NOS |
Adverse reaction to drug |
Adverse reaction to other central nervous system depressants and anesthetics |
Adverse reaction to drug |
Adverse reaction to other drugs primarily affecting the gastrointestinal system |
Adverse reaction to drug |
Adverse reaction to other muscle drugs |
Adverse reaction to drug |
Adverse reaction to other psychotropic agent |
Adverse reaction to drug |
Adverse reaction to other respiratory system drugs |
Adverse reaction to drug |
Adverse reaction to other skin, mucous membrane, ophthalmological, otorhinolaryngological and dental drugs |
Adverse reaction to drug |
Adverse reaction to psychotropic agent |
Adverse reaction to drug |
Adverse reaction to psychotropic agent NOS |
Adverse reaction to drug |
Adverse reaction to skin, mucous membrane, ophthalmological, otorhinolaryngological and dental drugs NOS |
Adverse reaction to drug |
Adverse reaction to sodium cromoglycate |
Adverse reaction to cromoglicic acid |
Adverse reaction to sodium fusidate |
Fusidic acid adverse reaction |
anafylaktisk reaktion orsakad av luftburet allergen |
Anaphylaxis |
Aerobacter aerogenes gastrointestinal tract infection |
Gastrointestinal infection caused by Klebsiella aerogenes |
Aerobacter meningitis |
Meningitis caused by Klebsiella aerogenes |
Aeromonas aquariorum |
Aeromonas dhakensis |
Aeromonas enteropelogenes |
Aeromonas trota |
Aeromonas tructi |
Aeromonas trota |
Aerosol or vapor inhalation for bronchodilation |
Inhaled bronchodilator therapy |
Affect finding |
Mood finding |
affektivt anfall |
Focal onset emotional epileptic seizure |
Afipia felis |
Afipia felis |
Agammaglobulinemia |
Congenital agammaglobulinemia |
aggression orsakad av intagbar alkohol |
Aggression caused by ethanol (finding) |
aggressivt digitalt papillärt papillom |
Digital papillary adenocarcinoma |
Agrobacterium radiobacter |
Rhizobium radiobacter (organism) |
Agrobacterium tumefaciens |
Rhizobium radiobacter (organism) |
shunt med Ahmedventil |
Valved ophthalmic drainage device (physical object) |
hjälpmedel för person med svår funktionsnedsättning |
Provision of aid for severe disability |
Aids for severely handicapped |
Provision of aid for severe disability |
Air |
Air |
Albright hereditary osteodystrophy |
Pseudohypoparathyroidism |
Albumin human + epoetin alfa 2.5mg/20000unt injection |
Epoetin alfa 20000 unit/mL solution for injection |
humant albumin 2,5 mg + epoetin alfa 20 000 IE injektionsvätska, lösning, flaska |
Epoetin alfa 20000 unit/mL solution for injection |
salbutamol 0,0417 %, lösning för inhalation |
Salbutamol sulfate 417 microgram/mL solution for inhalation |
salbutamol 200 mikrogram, kapsel |
Salbutamol (as salbutamol sulfate) 200 microgram/actuation powder for inhalation |
salbutamol 90 mikrogram per inhalation, aerosol |
Product containing only salbutamol in pulmonary dose form (medicinal product form) |
Albuterol sulfate + ipratropium bromide |
Product containing ipratropium and salbutamol (medicinal product) |
Albuterol sulfate + ipratropium bromide 103mcg/18mcg |
Ipratropium and salbutamol only product in pulmonary dose form |
salbutamolsulfat 103 mikrogram + ipratropiumbromid 18 mikrogram, aerosol |
Ipratropium and salbutamol only product in pulmonary dose form |
Albuterol sulfate 4mg tablet |
Salbutamol (as salbutamol sulfate) 4 mg oral tablet |
Albuterol+ipratropium bromide |
Product containing ipratropium and salbutamol (medicinal product) |
Alcaligenes aeutus |
Halomonas aquamarina |
Alcaligenes aquamarinus |
Halomonas aquamarina |
Alcaligenes defragrans |
Castellaniella defragrans (organism) |
Alcaligenes eutrophus |
Wautersia eutropha (organism) |
Alcaligenes fecalis ss. homari |
Halomonas aquamarina |
Alcaligenes paradoxus |
Variovorax paradoxus |
Alcaligenes xylosoxidans |
Achromobacter xylosoxidans (organism) |
Alcaligenes xylosoxidans, underart xylosoxidans |
Achromobacter xylosoxidans (organism) |
Alcaligenes xylosoxidans subsp xylosoxidans |
Achromobacter xylosoxidans (organism) |
Alcohol-induced polyneuropathy |
Alcoholic polyneuropathy |
alkoholhaltigt koltjäreextrakt 5 %, schampo |
Coal tar 50 mg/mL shampoo |
Alcoholic dementia NOS |
Psychosis caused by ethanol (disorder) |
Alcoholic dementia: [other] or [NOS] |
Psychosis caused by ethanol (disorder) |
Alcoholic psychoses |
Psychosis caused by ethanol (disorder) |
Alcoholic psychosis NOS |
Psychosis caused by ethanol (disorder) |
alkoholiserad släkting |
Family history of alcoholism |
allergi mot desinfektionsmedel innehållande aldehyd |
Allergy to aldehyde |
Aldehyde-lyase |
Aldehyde-lyase (substance) |
Alders syndrom |
Alder-Reilly body (finding) |
aldesleukin 18 megaenheter, pulver till injektionsvätska, flaska |
Product containing precisely aldesleukin 22 million unit/1 vial powder for conventional release solution for injection (clinical drug) |
Alendronate sodium |
Product containing alendronic acid (medicinal product) |
Alendronate sodium + cholecalciferol |
Product containing alendronic acid and colecalciferol (medicinal product) |
Alendronate sodium 13.05mg tablet |
Product containing precisely alendronic acid (as alendronate sodium) 10 milligram/1 each conventional release oral tablet (clinical drug) |
alendronatnatrium 70 mg/75 ml, oral lösning |
Product containing precisely alendronic acid (as alendronate sodium) 933 microgram/1 milliliter conventional release oral solution (clinical drug) |
Aleukemic leukemia |
Leukaemia |
aleukemisk mastcellsleukemi |
Mast cell leukemia (clinical) |
aleukemisk monocytleukemi |
Monocytic leukaemia |
aleukemisk monocytleukemi |
Monocytic leukemia (morphologic abnormality) |
aleukemisk myeloisk leukemi |
Myeloid leukemia |